Chronic Interstitial Lung Disease
نویسندگان
چکیده
منابع مشابه
Chronic interstitial lung disease in children.
Children's interstitial lung diseases (chILD) are increasingly recognised and contain many lung developmental and genetic disorders not yet identified in adult pneumology. Worldwide, several registers have been established. The Australasian Registry Network for Orphan Lung Disease (ARNOLD) has identified problems in estimating rare disease prevalence; focusing on chILD in immunocompetent patien...
متن کاملChronic interstitial lung disease in children
Métodos: Estudo retrospectivo de 25 pacientes imunocompetentes, de 2 meses a 17 anos, com doença pulmonar intersticial crônica, internados no Setor de Pneumologia, Serviço de Pediatria do Hospital dos ServidoresdoEstado, porumperíodode20anos (1984-2004).Seguiu-se protocolo para pneumopatias crônicas persistentes e selecionaram-se os casos de doença intersticial. Foram avaliados aspectos clínico...
متن کاملInterstitial Lung Disease in a Patient with Chronic Granulomatous Disease
BACKGROUND Chronic granulomatous disease (CGD) is an inherited phagocytes defect, characterized by defects of NADPH-oxidase and inability of bacterial killing, which leads to recurrent life-threatening infections. Respiratory problems, which are the major cause of morbidity in CGD, usually result from recurrent severe infections; however, vigorous inflammatory response could also cause respirat...
متن کاملInherited interstitial lung disease.
This article focuses on recent advances in the identification of genes and genetic polymorphisms that have been implicated in the development of human interstitial lung diseases. It focuses on the inherited mendelian diseases in which pulmonary fibrosis is part of the clinical phenotype and the genetics of familial idiopathic pulmonary fibrosis and other rare inherited interstitial lung disease...
متن کامل[Interstitial lung disease].
This concise article summarizes recent advances in the field of interstitial lung disease (ILD) with particular focus on clinically relevant findings. As a novel treatment option for idiopathic pulmonary fibrosis (IPF), pirfenidone has been granted marketing authorization in the European Union for the treatment of mild to moderate IPF. In contrast, the FDA refused to approve pirfenidone for the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Pediatrics
سال: 1998
ISSN: 0009-9228,1938-2707
DOI: 10.1177/000992289803701111